Skip to main content
. 2022 Apr 14;12:848187. doi: 10.3389/fonc.2022.848187

Table 2.

Multivariate competing risk regression model analysis.

Characteristics BCSD (N1 = 215,32.9%) OCSD (N2 = 438,67.1%)
Hazard ratio 95% CI p-value Hazard ratio 95% CI p-value
Age
 <65 1 1
 ≧65 1.64 1.214–2.211 0.0013 5.411 4.157–7.044 <0.0001
Race
 Non-Hispanic White 1 1
 Non-Hispanic Black 1.536 1.033–2.285 0.03 1.106 0.766–1.598 0.59
 others 1.326 0.937–1.877 0.11 0.712 0.540–0.939 0.016
Year of diagnosis
 1998–2006 1 1
 2007–2015 0.69 1.214–2.211 0.012 0.836 0.680–1.028 0.089
Marital status
 Married 1 1
 others 1.25 0.940–1.675 0.12 1.61 1.310–1.977 <0.0001
Grade
 I 1 1
 II 2.44 1.356–4.388 0.0029 0.99 0.787–1.244 0.93
 III+IV 3.78 2.064–6.936 <0.0001 0.989 0.730–1.341 0.94
ER Status
 Positive 1 1
 Negative 0.866 0.56–1.341 0.52 0.992 0.680–1.449 0.97
PR Status
 Positive 1 1
 Negative 1.81 1.234–2.640 0.0024 1.206 0.931–1.562 0.16
T Stage
 T0–1 1 1
 T2 2.31 1.646–3.240 <0.0001 1.256 1.017–1.552 0.034
 T3 2.71 1.430–5.119 0.0022 1.445 0.618–3.377 0.4
 T4 2.57 1.232–5.368 0.01 2.987 1.734–5.145 <0.0001
N Stage
 N0 1 1
 N1 1.85 1.303–2.612 <0.0001 0.953 0.741–1.227 0.71
 N2 3.49 2.088–5.819 <0.0001 1.025 0.566–1.858 0.93
 N3 6.45 3.721–11.187 <0.0001 0.591 0.210–1.662 0.32
Surgery
 NS-BCT 1 1
 NE-BCT 0.945 0.715–1.249 0.69 1.217 1.002–1.478 0.048
Radiation
 Yes 1 1
 No 1.38 1.018–1.858 0.038 1.753 1.454–2.112 <0.0001
Chemotherapy
 Yes 1 1
 No 1.04 0.731–1.481 0.83 2.311 1.681–3.178 <0.0001

NE-BCT, nipple-excising breast-conserving therapy; NS-BCT, nipple-sparing breast-conserving therapy; ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor 2; BCSD, breast-cancer-specific death; OCSD, other-cause-specific death.